ANTI-ALLERGIC AGENT FOR INFANTS

• US 20190201459A1
• Filed: 03/14/2019
• Published: 07/04/2019
• Est. Priority Date: 10/19/2015
• Status: Abandoned Application

• Current Assignee: Meiji Co Ltd (Meiji Holdings Company Limited)
• Original Assignee: Meiji Co Ltd (Meiji Holdings Company Limited)
• Inventors: Koshida, Shigeki, Terahara, Masaki
• Application Number:
  US16/353,135
• Publication Number:
  US 20190201459A1
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/304 having a modulation effect on allergy and risk of allergy
• CPC Class Codes: A23V 2250/5114 Dextrins, maltodextrins
• CPC Class Codes: A23V 2400/517 Bifidum
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

Provided herein is an anti-allergic agent for ameliorating an allergic disease in infants, particularly newborns, without causing side effects. The anti-allergic agent for infants comprises a bifidobacterium.

Claims

1. A method of treating an allergic disease of an infant comprising orally administering a bifidobacterium to the infant,

wherein the bifidobacterium is administered in an amount of 10⁸ or more in terms of the number of bacteria per day continuously for at least 1 month to decrease a serum IgE concentration of the infant,

the infant is a healthy infant, an immature infant, a premature infant, or a low-birth-weight infant, and

the infant is a child of newborn to less than one year age.

2. The method according to claim 1, wherein the bifidobacterium is Bifidobacterium bifidum.

3. The method according to claim 1, wherein the bifidobacterium is Bifidobacterium bifidum OLB6378 strain having the accession number:

NITE BP-31.

4. The method according to claim 1, wherein the bifidobacterium is administered in an amount of 10⁸ to 10¹² in terms of the number of bacteria per day continuously for at least 1 month.

5. The method according to claim 4, wherein the bifidobacterium is administered in an amount of 10⁸ to 10¹² in terms of the number of bacteria per day continuously for 1 to 12 months.

6. The method according to claim 1, wherein the bifidobacterium is administered in the form of a composition comprising the bifidobacterium and a granular dextrin.

7. The method according to claim 6, wherein a mass ratio of the bifidobacterium and the granular dextrin is 1:

100 to 1;

2.

8. The method according to claim 6, wherein the composition is packaged into a single package for each dose or multiple packages for each dose.

9. The method according to claim 1, wherein the bifidobacterium is heat-treated at 60 to 100 °

C. for 0.2 to 40 minutes.

10. The method according to claim 1, wherein the bifidobacterium is heat-treated at 100 to 300 °

C. for 0.01 to 0.5 minutes.

11. A method of preventing an allergic disease of an infant comprising orally administering a bifidobacterium to the infant,

wherein the bifidobacterium is administered in an amount of 10⁸ or more in terms of the number of bacteria per day continuously for at least 1 month to decrease a serum IgE concentration of the infant,

the infant is a healthy infant, an immature infant, a premature infant, or a low-birth-weight infant, and

the infant is a child of newborn to less than one year age.

12. The method according to claim 11, wherein the bifidobacterium is Bifidobacterium bifidum.

13. The method according to claim 11, wherein the bifidobacterium is Bifidobacterium bifidum OLB6378 strain having the accession number:

NITE BP-31.

14. The method according to claim 11, wherein the bifidobacterium is administered in an amount of 10⁸ to 10¹² in terms of the number of bacteria per day continuously for at least 1 month.

15. The method according to claim 14, wherein the bifidobacterium is administered in an amount of 10⁸ to 10¹² in terms of the number of bacteria per day continuously for 1 to 12 months.

16. The method according to claim 11, wherein the bifidobacterium is administered in the form of a composition comprising the bifidobacterium and a granular dextrin.

17. The method according to claim 16, wherein a mass ratio of the bifidobacterium and the granular dextrin is 1:

100 to 1;

2.

18. The method according to claim 16, wherein the composition is packaged into a single package for each dose or multiple packages for each dose.

19. The method according to claim 11, wherein the bifidobacterium is heat-treated at 60 to 100 °

C. for 0.2 to 40 minutes.

20. The method according to claim 11, wherein the bifidobacterium is heat-treated at 100 to 300 °

C. for 0.01 to 0.5 minutes.